Genetic Polymorphisms of IL-17F and TRAF3IP2 Could Be Predictive Factors of the Long-Term Effect of Infliximab against Crohn’s Disease

Table 5

Evaluation of a genetic test for response to IFX after 1 year of treatment of the CD patients with concomitant use of immunomodulators.

Factor	Number of CD patients (%)		OR (95% CI)	value
	Responders	Nonresponders
	= 20	= 8
Both G/G genotype of rs766748 in IL17F and C/C and C/A genotype of rs1883136 in TRAF3IP2	14 (70.0)	0 (0)	37.92 (1.890–761.1)	0.0019
Others	6 (30.0)	8 (100)

Factors were statistically analyzed by Fisher’s exact test.
IFX: infliximab; CD: Crohn’s disease; OR: odds ratio; CI: confidence interval.